September 22, 2024 – Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV), dedicated to developing innovative cancer therapies targeting DNA-damage response (DDR), is excited to announce a collaboration with Variational AI, known for its advanced Enki™ platform for drug discovery. This partnership aims to identify and develop new small-molecule therapies targeting DDR kinases.
As part of this agreement, Rakovina will gain exclusive rights to compounds generated by the Enki™ platform and the opportunity to license successful candidates for further development. Variational AI will focus on discovering new inhibitors for specific DDR targets identified by Rakovina, which will subsequently be evaluated at its University of British Columbia lab.
“This collaboration expands our therapeutic pipeline and enhances our drug discovery efforts,” said Executive Chairman Jeffrey Bacha. For more information, visit Variational AI and Rakovina Therapeutics.